EcoDrugPlus

Dna Methyltransferase 1

Ensembl ID : ENSFHEG00000001593
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase 1

Ensembl ID : ENSFHEG00000018640
Gene Symbol: LOC105922603
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSFHEG00000002423
Gene Symbol: LOC105919618
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSFHEG00000022308
Gene Symbol: TOP1
3 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSFHEG00000006175
Gene Symbol: TOP2A
3 Cross references
205 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSFHEG00000000488
Gene Symbol: TOP2B
3 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSFHEG00000017934
Gene Symbol: EML4
2 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSFHEG00000000575
Gene Symbol: EPHA3
3 Cross references
211 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSFHEG00000019584
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSFHEG00000018811
Gene Symbol: FAU
3 Cross references
299 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSFHEG00000011056
Gene Symbol: FYN
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSFHEG00000005777
Gene Symbol: GPR119
2 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).